The board of directors of HealthCare Global Enterprises Limited met on May 19, 2026, and approved the standalone and consolidated audited financial results for the quarter and year ended March 31, 2026. The company reported a strong quarterly performance, with revenue from operations reaching INR 34,847 lakhs for the quarter ended March 31, 2026, compared to INR 34,056 lakhs in the preceding quarter (December 31, 2025) and INR 32,280 lakhs in the corresponding quarter of the previous year (March 31, 2025).

Note: The profit analysis is based on available consolidated financial highlights.

HealthCare Global Enterprises Limited (HCG) is a prominent Indian healthcare provider specializing in oncology and fertility services. Under the “HCG” brand, the company operates the largest cancer care network in India, offering comprehensive treatment, diagnostic, and research services. Additionally, it manages fertility clinics under the “Milann” brand. In May 2026, the company announced the divestment of its entire stake in its fertility business, BACC Health Care Private Limited, to focus on its core oncology operations. The company has been actively expanding its clinical capabilities through investments in robotic surgery and theranostics, and it recently strengthened its management team with the appointment of a new Chief Financial Officer and AVP for Investor Relations. HCG also completed a rights issue in early 2026, raising funds to support its oncology expansion and deleveraging efforts.